The Combination of Olaratumab with Doxorubicin and Cisplatinum Regresses a Chemotherapy-Resistant Osteosarcoma in a Patient-Derived Orthotopic Xenograft Mouse Model

Chemotherapy-resistant osteosarcoma is a recalcitrant disease. It is a frequent cause of death to the patients who are usually adolescent or young adults. The goal of the present study was to determine the efficacy of the combination of olaratumab (OLA), doxorubicin (DOX), and cisplatinum (CDDP) on...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Transl Oncol
Hauptverfasser: Higuchi, Takashi, Sugisawa, Norihiko, Miyake, Kentaro, Oshiro, Hiromichi, Yamamoto, Norio, Hayashi, Katsuhiro, Kimura, Hiroaki, Miwa, Shinji, Igarashi, Kentaro, Bouvet, Michael, Singh, Shree Ram, Tsuchiya, Hiroyuki, Hoffman, Robert M.
Format: Artigo
Sprache:Inglês
Veröffentlicht: Neoplasia Press 2019
Schlagworte:
Original article
Online Zugang:https://ncbi.nlm.nih.gov/pmc/articles/PMC6624322/
https://ncbi.nlm.nih.gov/pubmed/31299622
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.tranon.2019.06.002
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!

Ähnliche Einträge